Novel pharmaceutical tegafur co-crystal and preparation method thereof

The invention belongs to the technical field of pharmaceutical co-crystals, particularly relates to a novel pharmaceutical tegafur co-crystal and a preparation method thereof, and more particularly relates to a novel co-crystal consisting of tegafur and an organic matter of 4-phenol benzamide. The co-crystal takes the tegafur as a pharmaceutical effective component (API); the selected matter for forming the co-crystal is the 4-phenol benzamide; the tegafur is connected with the 4-phenol benzamide by hydrogen bonds and a pi-pi accumulation effect; and the stoichiometric ratio (mole ratio) of both the tegafur and the 4-phenol benzamide is 1:1. The method for preparing the co-crystal disclosed by the invention is a temperature reduction type crystallization method which is simple and convenient to operate and easy to implement; used solvents are organic solvents which are low in boiling point and low in cost, such as acetonitrile and ketone; and convenience is provided for realizing industrial production.